QWM
AVDL

QP Wealth Management’s Avadel Pharmaceuticals AVDL Stock Holding History

QP Wealth Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,380
Closed -$221K – 73
2023
Q2 		$221K Buy
+13,380
New +$174K 0.35% 63

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

QP Wealth Management's AVDL Position: Q3 2023 in Review

QP Wealth Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2023, closing a stake of 13,380 shares — an estimated $221K sold.

QP Wealth Management first reported a position in AVDL in Q2 2023 and held it in 1 quarter. The position peaked at $221K in Q2 2023. 99 funds tracked by Wall St. Rank hold AVDL as of Q3 2023.

  • QP Wealth Management reported no remaining Avadel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • QP Wealth Management sold 13,380 Avadel Pharmaceuticals shares in Q3 2023, an estimated $221K.
  • QP Wealth Management first reported a position in Avadel Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • QP Wealth Management's Avadel Pharmaceuticals position peaked at $221K in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2023.

Based on QP Wealth Management's 13F filing for Q3 2023, filed 5 Oct 2023.